How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

5,269 results for

adhd exercise

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

5241. Safety and Tolerability Study of ABT-089 in Children With Attention-Deficit/Hyperactivity Disorder (ADHD)

: January 18, 2013 Sponsor: AbbVie (prior sponsor, Abbott) Information provided by (Responsible Party): AbbVie ( AbbVie (prior sponsor, Abbott) ) Study Details Study Description Go to Brief Summary: The purpose of this study is to test if the investigational medication ABT-089 is a safe and effective treatment for children with Attention Deficit Hyperactivity Disorder (ADHD). Condition or disease Intervention/treatment Phase Attention-Deficit/Hyperactivity Disorder Drug: ABT-089 Drug: placebo Phase 2 (...) table for eligibility information Ages Eligible for Study: 6 Years to 12 Years (Child) Sexes Eligible for Study: All Accepts Healthy Volunteers: No Criteria Inclusion Criteria: Have voluntarily signed an informed consent form. Meet diagnostic criteria for attention-deficit/hyperactivity disorder (ADHD) based on detailed evaluation and interview with parent(s). Subject is generally in good health based on medical history, physical examination, clinical lab tests and ECG. Subject weights at least 37

2008 Clinical Trials

5242. Safety, Tolerability and Efficacy Study of ABT-089 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)

Last Update Posted : January 18, 2013 Sponsor: AbbVie (prior sponsor, Abbott) Information provided by (Responsible Party): AbbVie ( AbbVie (prior sponsor, Abbott) ) Study Details Study Description Go to Brief Summary: The purpose of this study is to test if the investigational medication ABT-089 is a safe and effective treatment for adults with Attention-Deficit/Hyperactivity Disorder (ADHD). Condition or disease Intervention/treatment Phase Attention-Deficit/Hyperactivity Disorder Drug: ABT-089 (...) Criteria: Have voluntarily signed an informed consent form. Meet diagnostic criteria for attention-deficit/hyperactivity disorder (ADHD) based on detailed evaluation and interview with subject. Subject is generally in good health based on medical history, physical examination, clinical lab tests and ECG. Female subjects of child-bearing potential must have a negative urine pregnancy test at screening and baseline and agree to comply with applicable contraceptive requirements. Male subjects must agree

2008 Clinical Trials

5243. Dose Finding Study in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)(174007/P05805/MK-8777-003)

-week treatment periods will be separated by a 2-week placebo washout period. The primary objective is to compare the efficacy of various doses of MK-8777 to that of placebo in the treatment of ADHD symptoms in adults. Condition or disease Intervention/treatment Phase Attention Deficit Hyperactivity Disorder Drug: MK-8777 Drug: Placebo Phase 2 Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Actual Enrollment : 67 participants Allocation: Randomized (...) Attention Deficit Disorder with Hyperactivity Hyperkinesis Pathologic Processes Attention Deficit and Disruptive Behavior Disorders Neurodevelopmental Disorders Mental Disorders Dyskinesias Neurologic Manifestations Nervous System Diseases Signs and Symptoms

2008 Clinical Trials

5244. Study Evaluating the Safety and Efficacy of CLONICEL® to Treat Children and Adolescents With Attention Deficit Hyperactivity Disorder (ADHD)

Identifier: NCT00556959 Recruitment Status : Completed First Posted : November 12, 2007 Last Update Posted : March 24, 2010 Sponsor: Addrenex Pharmaceuticals, Inc. Information provided by: Addrenex Pharmaceuticals, Inc. Study Details Study Description Go to Brief Summary: The purpose of this study is to determine whether CLONICEL® (clonidine HCl sustained release) is a safe and effective treatment for children and adolescents with attention deficit hyperactivity disorder (ADHD). Condition or disease (...) Additional relevant MeSH terms: Layout table for MeSH terms Disease Attention Deficit Disorder with Hyperactivity Hyperkinesis Pathologic Processes Attention Deficit and Disruptive Behavior Disorders Neurodevelopmental Disorders Mental Disorders Dyskinesias Neurologic Manifestations Nervous System Diseases Signs and Symptoms Clonidine Analgesics Sensory System Agents Peripheral Nervous System Agents Physiological Effects of Drugs Antihypertensive Agents Sympatholytics Autonomic Agents Adrenergic alpha-2

2007 Clinical Trials

5245. A Safety and Efficacy Study of ABT-089 in Children With Attention-Deficit/Hyperactivity Disorder (ADHD)

: January 29, 2013 Sponsor: AbbVie (prior sponsor, Abbott) Information provided by (Responsible Party): AbbVie ( AbbVie (prior sponsor, Abbott) ) Study Details Study Description Go to Brief Summary: The purpose of this study is to test if the investigational medication ABT-089 is a safe and effective treatment for children with Attention-Deficit/Hyperactivity Disorder or ADHD. Condition or disease Intervention/treatment Phase Attention-Deficit/Hyperactivity Disorder Drug: ABT-089 Drug: atomoxetine Drug (...) , 2007 Last Update Posted: January 29, 2013 Last Verified: January 2013 Additional relevant MeSH terms: Layout table for MeSH terms Disease Attention Deficit Disorder with Hyperactivity Hyperkinesis Pathologic Processes Attention Deficit and Disruptive Behavior Disorders Neurodevelopmental Disorders Mental Disorders Dyskinesias Neurologic Manifestations Nervous System Diseases Signs and Symptoms Atomoxetine Hydrochloride Adrenergic Uptake Inhibitors Neurotransmitter Uptake Inhibitors Membrane

2007 Clinical Trials

5246. A Study to Evaluate the Efficacy and Safety of Two Doses of PF-03654746 in Adults With Attention Deficit Hyperactivity Disorder (ADHD).

will receive 3 weeks of treatment with PF-03654746, either a low dose (1 mg), or flexible dose (0.50 mg titrated up to 2 mg), and 3 weeks of placebo. A washout period will separate the 2 treatment periods. Participants will be required to washout of prior ADHD medication before entering the study. Participants will be required to come to the site for 10 visits over approximately a 10-week period. Condition or disease Intervention/treatment Phase Attention Deficit Hyperactivity Disorder Drug: PF-03654746 (...) for additonal information Responsible Party: Pfizer ClinicalTrials.gov Identifier: Other Study ID Numbers: A8801004 3-WK, CO MTD IN ADULTS W/ADHD ( Other Identifier: Alias Study Number ) First Posted: September 19, 2007 Results First Posted: February 19, 2016 Last Update Posted: February 19, 2016 Last Verified: January 2016 Additional relevant MeSH terms: Layout table for MeSH terms Disease Attention Deficit Disorder with Hyperactivity Hyperkinesis Pathologic Processes Attention Deficit and Disruptive

2007 Clinical Trials

5247. Safety and Efficacy of ADDERALL XR in the Treatment of Adolescents Aged 13-17 With Attention Deficit Hyperactivity Disorder (ADHD)

Last Verified: November 2007 Additional relevant MeSH terms: Layout table for MeSH terms Attention Deficit Disorder with Hyperactivity Attention Deficit and Disruptive Behavior Disorders Neurodevelopmental Disorders Mental Disorders Amphetamine Adderall Central Nervous System Stimulants Physiological Effects of Drugs Sympathomimetics Autonomic Agents Peripheral Nervous System Agents Dopamine Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Adrenergic Agents Adrenergic (...) Safety and Efficacy of ADDERALL XR in the Treatment of Adolescents Aged 13-17 With Attention Deficit Hyperactivity Disorder (ADHD) Safety and Efficacy of ADDERALL XR in the Treatment of Adolescents Aged 13-17 With Attention Deficit Hyperactivity Disorder (ADHD) - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have

2007 Clinical Trials

5248. Pilot Study Examining Effect for Dextroamphetamine to Treat Cocaine Dependence Plus Attention-deficit Hyperactivity Disorder (ADHD)

Posted: February 22, 2012 Last Verified: February 2012 Keywords provided by The University of Texas Health Science Center, Houston: cocaine ADHD attention hyperactivity drug dependence Additional relevant MeSH terms: Layout table for MeSH terms Disease Attention Deficit Disorder with Hyperactivity Hyperkinesis Cocaine-Related Disorders Substance-Related Disorders Pathologic Processes Attention Deficit and Disruptive Behavior Disorders Neurodevelopmental Disorders Mental Disorders Dyskinesias (...) . Thus, the present pilot study will determine the ability of dextroamphetamine to treat individuals with both cocaine dependence and ADHD. Condition or disease Intervention/treatment Phase Attention Deficit Disorder With Hyperactivity Cocaine-Related Disorders Substance-Related Disorders Drug: Placebo Drug: Dextroamphetamine SR Phase 2 Detailed Description: This double-blind, placebo-controlled pilot study will determine the ability of dextroamphetamine to treat comorbid cocaine dependence and ADHD

2007 Clinical Trials

5249. Efficacy and Effectiveness of Methylphenidate in Swedish Male Prison Inmates With Attention-deficit Hyperactivity Disorder (ADHD)

Disorder ADHD Prison Treatment Randomized Double-Blind Placebo Control Parallel Assignment Efficacy Study Additional relevant MeSH terms: Layout table for MeSH terms Attention Deficit Disorder with Hyperactivity Hyperkinesis Attention Deficit and Disruptive Behavior Disorders Neurodevelopmental Disorders Mental Disorders Dyskinesias Neurologic Manifestations Nervous System Diseases Signs and Symptoms Methylphenidate Central Nervous System Stimulants Physiological Effects of Drugs Dopamine Uptake (...) Efficacy and Effectiveness of Methylphenidate in Swedish Male Prison Inmates With Attention-deficit Hyperactivity Disorder (ADHD) Efficacy and Effectiveness of Methylphenidate in Swedish Male Prison Inmates With Attention-deficit Hyperactivity Disorder (ADHD) - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have

2007 Clinical Trials

5250. A Study of SPD465 in Young Adult Drivers With Attention-Deficit Hyperactivity Disorder (ADHD) Using Driving Simulators

provided by Shire: Attention-Deficit Hyperactivity Disorder (ADHD) Additional relevant MeSH terms: Layout table for MeSH terms Disease Attention Deficit Disorder with Hyperactivity Hyperkinesis Pathologic Processes Attention Deficit and Disruptive Behavior Disorders Neurodevelopmental Disorders Mental Disorders Dyskinesias Neurologic Manifestations Nervous System Diseases Signs and Symptoms (...) A Study of SPD465 in Young Adult Drivers With Attention-Deficit Hyperactivity Disorder (ADHD) Using Driving Simulators A Study of SPD465 in Young Adult Drivers With Attention-Deficit Hyperactivity Disorder (ADHD) Using Driving Simulators - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum

2007 Clinical Trials

5251. Long Acting Stimulant Treatment of Attention Deficit Hyperactivity Disorder (ADHD) in Young Children

: September 17, 2008 Results First Posted: February 21, 2018 Last Update Posted: February 21, 2018 Last Verified: February 2018 Keywords provided by Joan Daughton, MD, University of Nebraska: Attention Deficit Hyperactivity Disorder Stimulant Treatment Young Children Additional relevant MeSH terms: Layout table for MeSH terms Attention Deficit Disorder with Hyperactivity Hyperkinesis Attention Deficit and Disruptive Behavior Disorders Neurodevelopmental Disorders Mental Disorders Dyskinesias Neurologic (...) Long Acting Stimulant Treatment of Attention Deficit Hyperactivity Disorder (ADHD) in Young Children Long Acting Stimulant Treatment of Attention Deficit Hyperactivity Disorder (ADHD) in Young Children - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please

2008 Clinical Trials

5252. Pharmacokinetics of Two Extended-Release Formulations of Methylphenidate in Children With Attention Deficit Hyperactivity Disorder (ADHD)

, 2009 Last Verified: January 2009 Keywords provided by University Hospital Freiburg: ADHD Attention Deficit Disorder Attention Deficit an Disruptive Behavior Disorders Children Central Nervous System Stimulants Methylphenidate Pharmacokinetics Area Under Curve Therapeutic Equivalency Psychopharmacology Additional relevant MeSH terms: Layout table for MeSH terms Disease Attention Deficit Disorder with Hyperactivity Hyperkinesis Pathologic Processes Attention Deficit and Disruptive Behavior Disorders (...) objective of the study is to determine the pharmacokinetic parameters and bioequivalence of Ritalin LA compared to Medikinet retard, both given as oral o.d. doses of 20 mg over 7 days in children with ADHD. The secondary objectives are to assess the efficacy, safety and tolerability of Ritalin LA and Medikinet retard and the association of these parameters with plasma levels. Condition or disease Intervention/treatment Phase Attention Deficit Hyperactivity Disorder Drug: Methylphenidate Phase 1 Phase 2

2008 Clinical Trials

5253. Pharmacogenetic Study of Methylphenidate in Attention Deficit/Hyperactivity Disorder(ADHD)

, 2008 Last Update Posted: October 5, 2011 Last Verified: December 2010 Keywords provided by Hallym University Medical Center: ADHD, norepinephrine transporter pharmacogenetics Additional relevant MeSH terms: Layout table for MeSH terms Attention Deficit Disorder with Hyperactivity Hyperkinesis Attention Deficit and Disruptive Behavior Disorders Neurodevelopmental Disorders Mental Disorders Dyskinesias Neurologic Manifestations Nervous System Diseases Signs and Symptoms Methylphenidate Norepinephrine (...) and adverse effects of OROS-methylphenidate in treatment of ADHD. Condition or disease Intervention/treatment Phase Attention Deficit Disorder With Hyperactivity Methylphenidate Pharmacogenetics Genetic: norepinephrine transporter polymorphism, Phase 4 Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Estimated Enrollment : 150 participants Allocation: Non-Randomized Intervention Model: Single Group Assignment Masking: None (Open Label) Primary Purpose

2008 Clinical Trials

5254. PET Scanning of Adults With Attention Deficit Hyperactivity Disorder (ADHD)

: November 27, 2012 Keywords provided by National Institutes of Health Clinical Center (CC): Phospholipase A2 D2 Receptors Apomorphine Trimethobenzamide Attention Deficit Hyperactivity Disorder ADHD Healthy Volunteer HV Additional relevant MeSH terms: Layout table for MeSH terms Disease Attention Deficit Disorder with Hyperactivity Hyperkinesis Pathologic Processes Attention Deficit and Disruptive Behavior Disorders Neurodevelopmental Disorders Mental Disorders Dyskinesias Neurologic Manifestations (...) of a saline solution and again after injection of apomorphine, a medication that turns on dopamine receptors in the brain. The injections are given under the skin of the abdomen, about one and a half hours apart. Condition or disease Volunteer Attention Deficit Hyperactivity Disorder Detailed Description: A. Objective Attention deficit hyperactivity disorder (ADHD) is a heritable neurodevelopmental disorder with a reported male predominance that persists into adulthood and leads to significant morbidity

2006 Clinical Trials

5255. Study to Evaluate the Efficacy of Modafinil Treatment in Patients With Attention Deficit Hyperactivity Disorder (ADHD) Who Are Responders to Modafinil Treatment

: Attention-Deficit/Hyper Activity Disorder ADHD Additional relevant MeSH terms: Layout table for MeSH terms Disease Attention Deficit Disorder with Hyperactivity Hyperkinesis Pathologic Processes Attention Deficit and Disruptive Behavior Disorders Neurodevelopmental Disorders Mental Disorders Dyskinesias Neurologic Manifestations Nervous System Diseases Signs and Symptoms Modafinil Central Nervous System Stimulants Physiological Effects of Drugs Wakefulness-Promoting Agents Cytochrome P-450 CYP3A (...) ) who are responders to modafinil treatment. Condition or disease Intervention/treatment Phase Attention Deficit Hyperactivity Disorder Drug: Modafinil Phase 3 Detailed Description: The primary objective of the study is to evaluate the continued efficacy of modafinil treatment, compared to placebo treatment, in children and adolescents with attention-deficit/hyperactivity disorder (ADHD) who are responders to modafinil treatment, as assessed by the change from baseline (in this current study

2006 Clinical Trials

5256. Open Label, Multicentre Extension Study of Protocol 42603ATT3002 to Evaluate Safety of Prolonged Release OROS Methlyphenidate in Adults With Attention Deficit Hyperactivity Disorder (ADHD)

: CR011068 First Posted: March 28, 2006 Results First Posted: February 23, 2010 Last Update Posted: April 21, 2014 Last Verified: April 2014 Keywords provided by Janssen-Cilag International NV: Attention Deficit Hyperactivity Disorder Adult Long term safety Efficacy Quality of life Additional relevant MeSH terms: Layout table for MeSH terms Disease Attention Deficit Disorder with Hyperactivity Hyperkinesis Pathologic Processes Attention Deficit and Disruptive Behavior Disorders Neurodevelopmental (...) Open Label, Multicentre Extension Study of Protocol 42603ATT3002 to Evaluate Safety of Prolonged Release OROS Methlyphenidate in Adults With Attention Deficit Hyperactivity Disorder (ADHD) Open Label, Multicentre Extension Study of Protocol 42603ATT3002 to Evaluate Safety of Prolonged Release OROS Methlyphenidate in Adults With Attention Deficit Hyperactivity Disorder (ADHD) - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting

2006 Clinical Trials

5257. Study to Assess the Safety and Efficacy of NRP104 in Adults With Attention-Deficit Hyperactivity Disorder (ADHD)

Update Posted : July 2, 2009 Sponsor: New River Pharmaceuticals Information provided by: New River Pharmaceuticals Study Details Study Description Go to Brief Summary: The purpose of this study is to evaluate the safety and effectiveness of NRP104 administered as a daily morning dose (30, 50, and 70mg/day) compared to placebo in adults (18-55 years of age inclusive) diagnosed with moderate to severe Attention Deficit Hyperactivity Disorder (ADHD). Condition or disease Intervention/treatment Phase (...) Deficit Disorder with Hyperactivity Hyperkinesis Psychomotor Agitation Pathologic Processes Attention Deficit and Disruptive Behavior Disorders Neurodevelopmental Disorders Mental Disorders Dyskinesias Neurologic Manifestations Nervous System Diseases Signs and Symptoms Psychomotor Disorders Neurobehavioral Manifestations Lisdexamfetamine Dimesylate Central Nervous System Stimulants Physiological Effects of Drugs Dopamine Uptake Inhibitors Neurotransmitter Uptake Inhibitors Membrane Transport

2006 Clinical Trials

5258. Atomoxetine for Treating Cocaine Abuse in Adults With Attention Deficit Hyperactivity Disorder (ADHD)

Levin, New York State Psychiatric Institute: ADHD Cocaine Abuse Additional relevant MeSH terms: Layout table for MeSH terms Disease Attention Deficit Disorder with Hyperactivity Hyperkinesis Cocaine-Related Disorders Pathologic Processes Attention Deficit and Disruptive Behavior Disorders Neurodevelopmental Disorders Mental Disorders Dyskinesias Neurologic Manifestations Nervous System Diseases Signs and Symptoms Substance-Related Disorders Chemically-Induced Disorders Cocaine Atomoxetine (...) of cocaine abuse in adults with ADHD are significantly higher than they are in adults who do not have ADHD. Some clinicians suggest that adults with ADHD may abuse cocaine in order to self-medicate their ADHD symptoms. Atomoxetine is a drug that has been effective in treating ADHD. This study will evaluate the effectiveness of atomoxetine in reducing cocaine use in people with ADHD who abuse cocaine. Condition or disease Intervention/treatment Phase Attention Deficit Disorder With Hyperactivity Cocaine

2005 Clinical Trials

5259. Atomoxetine Asian Study in Adult Subjects With Attention-Deficit/Hyperactivity Disorder (ADHD)

-Deficit/Hyperactivity Disorder (ADHD). Condition or disease Intervention/treatment Phase Attention Deficit Hyperactivity Disorder Drug: Atomoxetine Phase 2 Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Actual Enrollment : 45 participants Intervention Model: Single Group Assignment Masking: None (Open Label) Primary Purpose: Treatment Official Title: An Open Study of Atomoxetine (LY139603) in Adult Subjects With Attention-deficit/Hyperactivity (...) Atomoxetine Asian Study in Adult Subjects With Attention-Deficit/Hyperactivity Disorder (ADHD) Atomoxetine Asian Study in Adult Subjects With Attention-Deficit/Hyperactivity Disorder (ADHD) - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one

2008 Clinical Trials

5260. Exercise responses in boys with attention deficit/hyperactivity disorder: effects of stimulant medication. (Abstract)

Exercise responses in boys with attention deficit/hyperactivity disorder: effects of stimulant medication. The effect of stimulant medication on exercise responses was studied in 14 boys (10.9 +/- 1.1 years) with attention deficit/hyperactivity disorder (ADHD).Exercise, with and without medication, was performed at 25 W, 50 W, and 75 W, followed by a peak exercise test.Submaximal heart rate (HR) was significantly higher by ~8 to 13 b.min(-1) across the three intensities during the medication (...) exercise are attenuated in some but not all boys with ADHD.

2008 Journal of attention disorders

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>